These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23995855)

  • 1. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
    Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
    Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
    Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
    Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S
    Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
    Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
    Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
    Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
    Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
    Engür S; Dikmen M; Öztürk Y
    Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
    Wei X; Zhou P; Lin X; Lin Y; Wu S; Diao P; Xie H; Xie K; Tang P
    Tumour Biol; 2014 Oct; 35(10):10213-21. PubMed ID: 25027405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.
    Runckel K; Barth MJ; Mavis C; Gu JJ; Hernandez-Ilizaliturri FJ
    Blood Adv; 2018 Dec; 2(23):3516-3525. PubMed ID: 30530779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.
    Tsai PC; Hernandez-Ilizaliturri FJ; Bangia N; Olejniczak SH; Czuczman MS
    Clin Cancer Res; 2012 Feb; 18(4):1039-50. PubMed ID: 22228637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.